Now live: European new issue coverage and historical data, for free. → Explore All Content & Delivery Channels
Log In
No results found for "".

Commentary & Deal Flow

PRICED: Dolcetto (Doc Pharma) E490m 5NC1 Sr Sec FRN E+312.5 at 100

HYC European Market: Deal Flow - General

Ticker

Security

IPT

Price Talk

Priced

IPT-Pxd

DOLCTH

Senior Secured Floating Rate Notes due 2032

E+325-337.5, 100

E+312.5-325, 100 WPIR

E+312.5, 100

-18.75

  • Price Progression:
    • Priced: 3mE+312.5bps at 100 (0% floor)
    • Price talk: E+312.5-325, 100 WPIR
    • IPT: E+325-337.5, 100
  • Issuer: Dolcetto Holdco S.p.A. (Doc Pharma)
  • Ticker: DOLCTH
  • Size: EUR490m
  • Format: Reg S / 144A
  • Security: Senior Secured Floating Rate Notes
  • Corporate Ratings: B3 (positive) / B (stable)
  • Issue Ratings: B3 / B
  • Maturity: 14-July-2032 (5y)
  • Optional Redemption: NC1 (23-September-2027 at 100) (MWC B+50bp)
  • Change of Control: CoC at 101
  • Payment dates: Quarterly, 15-March / 15-June / 15-September / 15-December, starting 15-December-2026
  • Day Count: Actual/360
  • Denominations: 100kx1k
  • Reg S ISIN: XS3516306712
  • 144A ISIN: XS3516307108
  • Listing: Luxembourg Stock Exchange
  • Law: New York law
  • Sole Global Coordinator and Physical Bookrunner: BNP Paribas (B&D)
  • Settles: 1-October-2026 (T+6)
  • Trade Date: 23-September-2026
  • UOP: Together with cash on balance sheet to redeem existing $490m FRN due 07/14/32 (callable at 100), pay costs, fees, and expenses
  • Equity sponsor: TPG (80.4%), ICG (17.9%)
  • Biz: Leading Italian generic pharmaceutical company
  • HQ: Milan, Italy

Marketing:

  • Investor Call: Global Investor Call (GIC) 22-September at 09:00 UKT / 10:00 CET
  • Fixed income investor meetings: 1-on-1s 22-September
  • Books closed: 14:15 UKT / 15:15 CET, 23-September-2026
  • FTT: 7:30 UKT, 24-September-2026
  • ToE: 15:49 UKT, 23-September-2026

https://evercall.co/oacc/14278


We use functional cookies to make this site work properly and marketing cookies to personalize content. By continuing or clicking "Ok", you consent to our use of cookies. See our Cookie Policy for more information.
By continuing, you agree to FINSIGHT's Terms of Use and Privacy Policy.